Research
Intro text. Ut enim ad minim veniam, quis nostrud exercitation ullamco. Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullaud exercitation ullamco.
-
NIHR Oncology Translational Research Collaboration (O-TRC) IO
The use of immunotherapy is rapidly expanding - more biologic targets, more approved treatments, more combinations in more cancer types at earlier stages. Immunotherapy induced hepatitis is a common complication typically managed with high dose corticosteroids. The management of immunotherapy hepatitis is mostly informed by expert consensus with little data to support this. This survey aims to describe the current clinical management of immunotherapy hepatitis across the UK - in particular are there areas of clinical equipoise that could be addressed by clinical trials to improve our supportive care of this common complication.
Read More
-
ASCO 2023 - Immunotherapy in Melanoma
Understanding the Benefits and Toxicities
Intro text. Ut enim ad minim veniam, quis nostrud exercitation ullamco. Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullaud exercitation ullamco.
Read More
